Preemptive plerixafor based mobilization strategy in multiple myeloma patients for autologous stem cell transplantation

被引：1
|
作者：
Vadlamani, Surya Prakash [1 ]
Kumar, Lalit [1 ]
Pramanik, Raja [1 ]
Varshney, Ankur Nandan [1 ]
机构：
[1] All India Inst Med Sci, Delhi, India
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
mobilisation; Multiple myeloma; plerixafor;
D O I：
10.1016/j.clml.2019.09.497
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-171
引用
收藏
页码：E303 / E303
页数：1
相关论文
共 50 条
  • [1] The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma
    Uysal, Ayse
    Erkurt, Mehmet Ali
    Kuru, Irfan
    Kaya, Emin
    Berber, Ilhami
    Sarici, Ahmet
    Bicim, Soykan
    Kaya, Ahmet
    Hidayet, Emine
    MARMARA MEDICAL JOURNAL, 2023, 36 (01): : 65 - 71
  • [2] Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma
    Avigan, Zachary M.
    Arinsburg, Suzanne
    Pan, Darren
    Mark, Tomer
    Fausel, Christopher
    Bubalo, Joseph
    Milkovich, Gary
    Chari, Ajai
    Richter, Joshua
    BONE MARROW TRANSPLANTATION, 2024, 59 (10) : 1440 - 1448
  • [3] Cost-Effectiveness Analysis of Motixafortide Versus Plerixafor in Stem Cell Mobilization for Autologous Transplantation in Patients with Multiple Myeloma
    Lamotte, Mark
    DiPersio, John F.
    Siegel, David
    Meron, Haddas
    Gerlier, Laetitia
    BLOOD, 2022, 140 : 10794 - 10795
  • [4] Pharmacoeconomic Impact of Upfront Use Plerixafor for Autologous Stem Cell Mobilization in Multiple Myeloma Patients
    Isola, Luis
    Banoff, Karen M.
    Kim, Sara S.
    BLOOD, 2011, 118 (21) : 910 - 910
  • [5] PHARMACOECONOMIC IMPACT OF UPFRONT USE PLERIXAFOR FOR AUTOLOGOUS STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS
    Isola, L.
    Banoff, K.
    Kim, S. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S237 - S237
  • [6] Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure
    Worel, Nina
    Fritsch, Gerhard
    Agis, Hermine
    Boehm, Alexandra
    Engelich, Georg
    Leitner, Gerda C.
    Geissler, Klaus
    Gleixner, Karoline
    Kalhs, Peter
    Buxhofer-Ausch, Veronika
    Keil, Felix
    Kopetzky, Gerhard
    Mayr, Viktor
    Rabitsch, Werner
    Reisner, Regina
    Rosskopf, Konrad
    Ruckser, Reinhard
    Zoghlami, Claudia
    Zojer, Niklas
    Greinix, Hildegard T.
    JOURNAL OF CLINICAL APHERESIS, 2017, 32 (04) : 224 - 234
  • [7] Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario
    Kouroukis, C. T.
    Varela, N. P.
    Bredeson, C.
    Kuruvilla, J.
    Xenocostas, A.
    CURRENT ONCOLOGY, 2016, 23 (04) : E409 - E430
  • [8] Combination of plerixafor and G-CSF for mobilization: Impact on engraftment in autologous stem cell transplantation for multiple myeloma
    Zanabili Al-Sibai, J.
    Garcia Gala, J. M.
    Morais Bras, L. R.
    Martinez Revuelta, E.
    Avila Idrovo, L. F.
    Arias Fernandez, T.
    Gonzalez Rodriguez, A. P.
    Colado Varela, E.
    Palomo Moraleda, MdelP
    Gonzalez Huerta, A. J.
    Gonzalez Muniz, S.
    Castanon Fernandez, C.
    Sole Magdalena, A.
    Garcia Menendez-Tevar, F.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S137 - S137
  • [9] Plerixafor in myeloma and lymphoma patients undergoing autologous stem cell transplantation
    Zielinska, P.
    Markiewicz, M.
    Helbig, G.
    Mietla, M. Dzierzak
    Yrcz-Krzemien, S.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S347 - S347
  • [10] Plerixafor might overcome the detrimental effect of previous autologous stem cell transplantation on haematopoietic stem cell mobilization in myeloma patients
    Basak, G.
    Jaksic, O.
    Mikala, G.
    Koristek, Z.
    Basic-Kinda, S.
    Mayer, J.
    Masszi, T.
    Knopinska-Posluszny, W.
    Giebel, S.
    Labar, B.
    Wiktor-Jedrzejczak, W.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S333 - S334
12345